重组促甲状腺激素与左甲状腺素撤药在N1甲状腺癌131I治疗中的比较:大型匹配队列研究
法国多中心回顾性匹配队列研究纳入404例pT1-T3/N1/M0分化型甲状腺癌患者,比较rhTSH与THW准备后首次RAI评估的无病状态。rhTSH组无病率75.1%,THW组71.9%,差异3.3%(-6.6至13.0),上限<15%达到非劣效。末次评估完全缓解率分别为83.5%和81.5%。
要点
- rhTSH准备在N1 DTC患者首次RAI后无病状态上非劣于THW
- 两组末次评估完全缓解率相近,且不受已知预后因素影响
- rhTSH可作为N1 DTC患者RAI前准备的替代选择
核心结论
- 在pT1-T3/N1/M0分化型甲状腺癌患者中,rhTSH准备首次RAI治疗在首次评估无病状态和约3年完全缓解率上非劣于THW。
研究设计与样本
- 法国多中心回顾性研究,共404例pT1-T3/N1/M0 DTC患者,rhTSH组205例,THW组199例,按年龄(<45/≥45岁)、N1淋巴结数(≤5/>5枚)和分期(pT1-T2/pT3)匹配。
主要发现
- 末次评估(rhTSH组29.7±20.7个月,THW组36.7±23.8个月)完全缓解率分别为83.5%和81.5%。
- 两组病理特征和初始RAI活度(3.27±1.00 GBq)相似。
- 结果不受任何已知预后因素影响。
关键数值与推荐
- 无病状态定义为甲状腺球蛋白水平低于阈值且超声正常。
临床怎么用
- 对于pT1-T3/N1/M0分化型甲状腺癌患者,初次RAI治疗前准备可考虑使用rhTSH替代THW。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 两组末次评估时间不一致(rhTSH组29.7±20.7个月,THW组36.7±23.8个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Recombinant human thyrotropin (rhTSH) has been shown to be an effective stimulation method for radioactive iodine (RAI) therapy in differentiated thyroid cancer, including in those with nodal metastases (N1 DTC). OBJECTIVES: To demonstrate the noninferiority of rhTSH vs thyroid hormone withdrawal (THW) in preparation to RAI regarding disease status at the first evaluation in the real-life setting in patients with N1 DTC. DESIGN: This was a French multicenter retrospective study. Groups were matched according to age (<45/≥45 years), number of N1 nodes (≤5/>5 lymph nodes), and stage (pT1-T2/pT3). RESULTS: The cohort consisted of 404 patients pT1-T3/N1/M0 DTC treated with rhTSH (n = 205) or THW (n = 199). Pathological characteristics and initially administrated RAI activities (3.27 ± 1.00 GBq) were similar between the two groups. At first evaluation (6 to 18 months post-RAI), disease-free status was defined by thyroglobulin levels below threshold and a normal ultrasound. Disease-free rate was not inferior in the rhTSH group (75.1%) compared with the THW group (71.9%). The observed difference between the success rates was 3.3% (-6.6 to 13.0); rhTSH was therefore considered noninferior to THW because the upper limit of this interval was <15%. At the last evaluation (29.7 ± 20.7 months for rhTSH; 36.7 ± 23.8 months for THW), 83.5% (rhTSH) and 81.5% (THW) of patients achieved a complete response. This result was not influenced by any of the known prognostic factors. CONCLUSIONS: A preparation for initial RAI treatment with rhTSH was noninferior to that with THW in our series of pT1-T3/N1/M0-DTC on disease-free status outcomes at the first evaluation and after 3 years.
引用
- Leenhardt L, Leboulleux S, Bournaud C, et al. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod). J Clin Endocrinol Metab. 2019. PMID: 30398518. doi:10.1210/jc.2018-01589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。